Co-Diagnostics Inc. (CODX)

NASDAQ: CODX · Real-Time Price · USD

0.36

0.01 (2.56%)

At close: May 01, 2025, 2:46 PM

2.56% (1D)

Bid	0.36
Market Cap	12.22M
Revenue (ttm)	1.2M
Net Income (ttm)	-37.64M
EPS (ttm)	-1.24
PE Ratio (ttm)	-0.29
Forward PE	3.65
Analyst	Hold

Ask	0.37
Volume	29,645
Avg. Volume (20D)	197,498
Open	0.36
Previous Close	0.35
Day's Range	0.35 - 0.37
52-Week Range	0.28 - 2.23
Beta	1.21

About CODX

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to ...

[Read more]

Industry Medical - Devices

Sector Healthcare

IPO Date Jul 12, 2017

Employees 132

Stock Exchange NASDAQ

Ticker Symbol CODX

Website https://www.codiagnostics.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for CODX stock is "Hold." The 12-month stock price forecast is $5.5, which is an increase of 1410.99% from the latest price.

Stock Forecasts

Next Earnings Release

Co-Diagnostics Inc. is scheduled to release its earnings on May 8, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

7 months ago

+7.2%

Co-Diagnostics shares are trading higher after the... Unlock content with Pro Subscription

8 months ago

+12.9%

Co-Diagnostics shares are trading higher after the CDC announced free at home Covid 19 test delivery programs will reopen in late September.

News

4 weeks ago · zacks.com

All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy

CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · zacks.com

Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.

1 month ago · seekingalpha.com

Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants ...

2 months ago · benzinga.com

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

On Friday, Co-Diagnostics, Inc. CODX withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test for 510(k) clearance.